Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic

Robert D. McBane, Victor D. Torres Roldan, Alexander S. Niven, Rajiv K. Pruthi, Pablo Moreno Franco, Jane A. Linderbaum, Ana I. Casanegra, Lance J. Oyen, Damon E. Houghton, Ariela L. Marshall, Narith N. Ou, Jason L. Siegel, Waldemar E. Wysokinski, Leslie J. Padrnos, Candido E. Rivera, Gayle L. Flo, Fadi E. Shamoun, Scott M. Silvers, Tarek Nayfeh, Meritxell UrtechoSahrish Shah, Raed Benkhadra, Samer Mohir Saadi, Mohammed Firwana, Tabinda Jawaid, Mustapha Amin, Larry J. Prokop, M. Hassan Murad

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

A higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.

Original languageEnglish (US)
Pages (from-to)2467-2486
Number of pages20
JournalMayo Clinic proceedings
Volume95
Issue number11
DOIs
StatePublished - Nov 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic'. Together they form a unique fingerprint.

Cite this